Prurigo Nodularis Linked to Sleep Disorders and Increased CV Risk: Study Finds Medha Baranwal16 Dec 2024 8:00 PM ISTUSA: Recent research published in the Archives of Dermatological Research indicates that individuals with prurigo nodularis (PN) are at a...
Phase 3 Trial Confirms Nemolizumab's Efficacy for Moderate to Severe Prurigo Nodularis Medha Baranwal12 Dec 2024 8:30 PM ISTGermany: The OLYMPIA 1 Phase 3 randomized clinical trial has revealed promising outcomes for nemolizumab, a monoclonal antibody targeting...
Prurigo nodularis closely associated with atopic dermatitis, finds recent research Jacinthlyn Sylvia23 Oct 2024 8:45 PM ISTThe substantial correlation between prurigo nodularis (PN) and atopic dermatitis (AD) has been highlighted by a recent systematic review published in...
Worst Itch Numeric Rating Scale may Revolutionize Prurigo Nodularis Treatment Evaluation: JAMA Medha Baranwal2 July 2024 6:30 AM ISTUSA: Prurigo Nodularis (PN), a debilitating skin condition characterized by intensely itchy nodules, poses a significant challenge to patients and...
Nemolizumab and topical steroid combination effective against prurigo nodularis: Study Jacinthlyn Sylvia15 May 2024 10:00 PM ISTA recent study from Japan unveiled promising outcomes in the stride to effectively manage Prurigo Nodularis (PN) which is a chronic inflammatory skin...
Dupilumab may reduce pruritus and lesion appearance among patients with prurigo nodularis Jacinthlyn Sylvia13 Dec 2023 5:30 AM ISTPrurigo nodularis (PN) is a distressing inflammatory skin condition marked by itchy, reddish lesions.Dupilumab may reduce pruritus and lesion...
Tralokinumab beneficial for patients with prurigo nodularis-like phenotype atopic dermatitis: JAAD Medha Baranwal4 July 2023 9:15 AM ISTItaly: Tralokinumab, an IL-13 monoclonal antibody, showed clinical improvement in patients with prurigo nodularis-like phenotype atopic dermatitis...
Sanofi Dupixent gets European Commission nod for Prurigo Nodularis Ruchika Sharma18 Dec 2022 5:30 PM ISTParis: Regeneron Pharmaceuticals, Inc. and Sanofi have announced that the European Commission (EC) has expanded the marketing authorization for...
Sanofi Dupixent recommended for EU approval by CHMP for prurigo nodularis treatment Ruchika Sharma13 Nov 2022 4:30 PM ISTDupixent is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways and is not...
FDA approves dupilumab as first and only treatment Indicated for Prurigo Nodularis Dr. Kamal Kant Kohli2 Oct 2022 7:30 PM ISTPrurigo nodularis is a chronic, debilitating skin disease with underlying type 2 inflammation and its impact on quality of life is one of the highest...
Sanofi Prurigo nodularis drug Dupixent gets USFDA okay Ruchika Sharma30 Sept 2022 4:30 PM ISTParis: Sanofi has announced that the U.S. Food and Drug Administration (USFDA) has approved Dupixent (dupilumab) for the treatment of adult patients...
Dupilumab significantly improves skin lesions and itching among treated patients with prurigo nodularis Dr. Kamal Kant Kohli21 Sept 2022 8:00 PM ISTDupilumab improves skin lesions and itching among treated patients with prurigo nodularis, reveals Initrial data presented at the European Academy of...
